A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. TransCode Therapeutics Inc’s current trading price is -99.76% away from its 52-week high, while its distance from the 52-week low is 42.18%. The stock’s price range for this time frame has been between $0.22 and $128.00. The trading volume of the company’s shares in the Healthcare reached around 1.39 million for the day, which was evidently lower than the average daily volume of 1.4 million over the last three months.
TransCode Therapeutics Inc’s stock market performance has been somewhat irregular. The 1-year high for the company’s stock was recorded at $128.00 on 09/25/23, with the lowest value being $0.22 on 08/14/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
TransCode Therapeutics Inc (RNAZ) has experienced a quarterly decline of -69.89% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.30M and boasts a workforce of 10 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.7308, with a change in price of -0.3000. Similarly, TransCode Therapeutics Inc recorded 1,613,975 in trading volume during the last 100 days, posting a change of -49.42%.
How RNAZ’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for RNAZ stands at 0.17. Similarly, the long-term debt-to-equity ratio is also 0.00.
RNAZ Stock Stochastic Average
TransCode Therapeutics Inc’s raw stochastic average for the past 50 days is currently at 11.92%. This represents a fall from the raw stochastic average of the last 20 days, which was recorded at 38.89%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 56.51% and 63.64%, respectively.
RNAZ Stock Price Performance Analysis
The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. Year to date metric has recorded a loss of -95.34%.However, over the last six months, we can see a stronger performance of -53.91%. Over the last 30 days, the price of RNAZ has fallen by 10.43%. And in the last five days, it has surged by 17.93%.
